About: Neuropsychiatric adverse events of chloroquine: A real-world pharmacovigilance study using the FAERS database

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neuropsychiatric adverse events of chloroquine: A real-world pharmacovigilance study using the FAERS database Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Neuropsychiatric adverse events of chloroquine: A real-world pharmacovigilance study using the FAERS database
Creator	Toda, Tatsushi Iwata, Atsushi Mano, Tatsuo Sato, Sato, Kenichiro
Source	MedRxiv
abstract	Objectives: In early April 2020, the antimalarial drug, chloroquine, has been approved as an emergency treatment for the coronavirus disease 2019 (COVID-19) in the United States and in Europe. Although infrequent, neuropsychiatric symptoms have been reported in patients who received chloroquine for the treatment of malaria or autoimmune diseases. In this study, we investigated these adverse events (AEs) using a large self-reporting database. Materials and Methods: We conducted a disproportionality analysis for the detection of neuropsychiatric AE signals associated with the use of chloroquine (or hydroxychloroquine), reported to FAERS database between the fourth quarter of 2012 and the fourth quarter of 2019. Adjusted reporting odds ratio (ROR) for the development of each of the neuropsychiatric AEs following the use of chloroquine was calculated using a multilevel model. Results: We included 2,389,474 AE cases, among which 520 cases developed neuropsychiatric AE following the use of chloroquine. Exposure to chloroquine was associated with a statistically significant high reporting of amnesia, delirium, hallucinations, depression, and loss of consciousness, (lower 95% confidence interval of the adjusted ROR > 1), although the degree of increase in their ROR was limited. There was no statistically significant high reporting of any other neuropsychiatric AE, including suicide, psychosis, confusion, and agitation. Conclusion: Current pharmacovigilance study results did not suggest any potential link between the use of chloroquine and an increased risk of suicide, psychosis, confusion, and agitation, which would be informative during the emergency use of chloroquine for the treatment of COVID-19.
has issue date	2020-04-14(xsd:dateTime)
bibo:doi	10.1101/2020.04.10.20061358
has license	medrxiv
sha1sum (hex)	b8a5c53047bbc39fc1d7c170c1086a78f60f3153
schema:url	https://doi.org/10.1101/2020.04.10.20061358
resource representing a document's title	Neuropsychiatric adverse events of chloroquine: A real-world pharmacovigilance study using the FAERS database
resource representing a document's body	covid:b8a5c53047bbc39fc1d7c170c1086a78f60f3153#body_text
is schema:about of	named entity 'database' named entity 'pharmacovigilance' named entity 'OBJECTIVES' covid:arg/b8a5c53047bbc39fc1d7c170c1086a78f60f3153 named entity 'coronavirus disease 2019' named entity 'Neuropsychiatric' named entity '2019 in the United States' named entity 'April 2020' named entity 'Europe' named entity 'adverse events' named entity 'post-marketing surveillance' named entity 'mefloquine' named entity 'FDA' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'coma' named entity 'medRxiv' named entity 'COVID-19' named entity 'preprint' named entity 'Adverse Event' named entity 'preprint' named entity 'mefloquine' named entity 'informed consent' named entity '95% CI' named entity 'suicide' named entity 'neuropsychiatric' named entity 'chloroquine' named entity 'medRxiv' named entity 'mefloquine' named entity 'suicide' named entity 'REAC' named entity '95% CI' named entity 'chloroquine' named entity 'psychosis' named entity 'cohort studies' named entity 'COVID' named entity 'preprint' named entity 'medRxiv' named entity 'somnolence' named entity 'malaria' named entity 'chloroquine' named entity 'European Medicines Agency' named entity 'statistically significant' named entity 'statistical analyses' named entity 'chloroquine' named entity 'medRxiv' named entity 'aROR' named entity 'contingency table' named entity 'peer-reviewed' named entity 'adverse event' named entity 'Plaquenil' named entity 'altered mental status' named entity 'preprint' named entity 'vaccines' named entity 'COVID' named entity 'hallucination' named entity 'chloroquine' named entity 'adverse events' named entity 'FDA' named entity 'development of drugs' named entity 'preprint' named entity 'preprint' named entity 'FAERS' named entity 'preprint' named entity 'chloroquine' named entity 'neuropsychiatric' named entity 'CC-BY-NC-ND 4.0' named entity 'CC-BY-NC-ND 4.0' named entity 'preprint' named entity 'statistically significant' named entity 'AEs' named entity 'preprint' named entity 'headache' named entity 'medRxiv' named entity 'cardiotoxic' named entity 'medRxiv' named entity 'psychosis' named entity 'preprint' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software